PMID- 7697608
OWN - NLM
STAT- MEDLINE
DCOM- 19950504
LR  - 20190620
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 75
IP  - 8
DP  - 1995 Apr 15
TI  - Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy.
PG  - 2169-73
AB  - BACKGROUND: Acquired immune deficiency syndrome (AIDS)-related Kaposi's sarcoma 
      (KS) is a common complication of patients infected with human immunodeficiency 
      virus and can cause significant morbidity. Long term therapy with standard 
      chemotherapeutic regimens has been limited by relatively short durations of 
      response and potential toxicity. Once therapy is discontinued, the disease 
      typically progresses. Liposome-encapsulated doxorubicin (DOX-SL) currently is 
      being evaluated for treating patients with AIDS-related KS. Early reports suggest 
      a high response rate and good patient tolerance permitting continued therapy for 
      extended periods. METHODS: Patients with AIDS-related KS are treated with a 
      DOX-SL regimen every 2-3 weeks and are followed carefully for evidence of adverse 
      treatment effects. RESULTS: Two cases of hand-foot syndrome (HFS) in patients 
      receiving DOX-SL for AIDS-related KS are reported. Tissue studies demonstrated 
      changes consistent with a toxic effect of the drug on keratinocytes. Hand-foot 
      syndrome was reversible once treatment stopped; however, treatment cessation 
      resulted in primary disease recurrence. CONCLUSIONS: Hand-foot syndrome can be 
      debilitating and may be a limiting factor in the prolonged use of DOX-SL for 
      AIDS-related KS for some patients. It is critical for clinicians using this drug 
      to identify this side effect to limit HFS-associated morbidity.
FAU - Gordon, K B
AU  - Gordon KB
AD  - Department of Dermatology, Northwestern University Medical School, Chicago, IL 
      60611, USA.
FAU - Tajuddin, A
AU  - Tajuddin A
FAU - Guitart, J
AU  - Guitart J
FAU - Kuzel, T M
AU  - Kuzel TM
FAU - Eramo, L R
AU  - Eramo LR
FAU - VonRoenn, J
AU  - VonRoenn J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Drug Carriers)
RN  - 0 (Liposomes)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/complications
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Doxorubicin/*administration & dosage/*adverse effects/therapeutic use
MH  - Drug Carriers
MH  - Drug Eruptions/*etiology/pathology
MH  - Foot
MH  - Hand
MH  - Humans
MH  - Infusions, Intravenous
MH  - Liposomes
MH  - Male
MH  - Sarcoma, Kaposi/*drug therapy/etiology
MH  - Syndrome
EDAT- 1995/04/15 00:00
MHDA- 1995/04/15 00:01
CRDT- 1995/04/15 00:00
PHST- 1995/04/15 00:00 [pubmed]
PHST- 1995/04/15 00:01 [medline]
PHST- 1995/04/15 00:00 [entrez]
AID - 10.1002/1097-0142(19950415)75:8<2169::aid-cncr2820750822>3.0.co;2-h [doi]
PST - ppublish
SO  - Cancer. 1995 Apr 15;75(8):2169-73. doi: 
      10.1002/1097-0142(19950415)75:8<2169::aid-cncr2820750822>3.0.co;2-h.